Media headlines about Ohr Pharmaceuticals (NASDAQ:OHRP) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ohr Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.9476803217111 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

Several research analysts have issued reports on OHRP shares. Zacks Investment Research upgraded Ohr Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research note on Tuesday, July 18th. HC Wainwright set a $10.00 target price on Ohr Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 16th.

Shares of Ohr Pharmaceuticals (NASDAQ OHRP) opened at 0.64 on Monday. The stock has a 50 day moving average price of $0.63 and a 200-day moving average price of $0.76. The firm’s market capitalization is $35.98 million. Ohr Pharmaceuticals has a 52 week low of $0.56 and a 52 week high of $4.05.

Ohr Pharmaceuticals (NASDAQ:OHRP) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.18. On average, equities research analysts forecast that Ohr Pharmaceuticals will post ($0.67) earnings per share for the current year.

WARNING: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at

Insider Buying and Selling by Quarter for Ohr Pharmaceuticals (NASDAQ:OHRP)

Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.